A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.

Giorgio Scagliotti,Denis Moro-Sibilot,Jens Kollmeier,Adolfo Favaretto,Eun Kyung Cho, Heidrun Grosch,Martin Kimmich,Nicolas Girard,Chun-Ming Tsai,Te-Chun Hsia,Matteo Brighenti,Christian Schumann,Xuejing Aimee Wang,Sameera R Wijayawardana,Aaron M Gruver,Johan Wallin,Kambiz Mansouri,Volker Wacheck,Gee-Chen Chang

Journal of Thoracic Oncology（2020）

引用 49|浏览86

暂无评分

摘要

No statistically significant difference in PFS was noted in the intent-to-treat population. Exploratory analysis confirmed that high MET expression is a negative prognostic marker for patients treated with erlotinib, indicating that emibetuzumab plus erlotinib may provide clinically meaningful benefit.

查看译文

关键词

NSCLC,First-line EGFR mutation,MET,Acquired resistance,Antibody

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要